Best clinical response
| . | AITL, n = 13 . | PTCL-NOS, n = 21 . | Total, N = 34 . |
|---|---|---|---|
| Best clinical response, n (%)* | |||
| CR | 5 (38) | 3 (14) | 8 (24) |
| PR | 2 (15) | 4 (19) | 6 (18) |
| SD | 3 (23) | 3 (14) | 6 (18) |
| PD | 3 (23) | 11 (52) | 14 (41) |
| Objective response rate, n (%) | 7 (54) | 7 (33) | 14 (41) |
| 95% CI for objective response rate† | 25.1, 80.8 | 14.6, 57 | 24.6, 59.3 |
| Disease control rate, n (%)‡ | 10 (77) | 10 (48) | 20 (59) |
| . | AITL, n = 13 . | PTCL-NOS, n = 21 . | Total, N = 34 . |
|---|---|---|---|
| Best clinical response, n (%)* | |||
| CR | 5 (38) | 3 (14) | 8 (24) |
| PR | 2 (15) | 4 (19) | 6 (18) |
| SD | 3 (23) | 3 (14) | 6 (18) |
| PD | 3 (23) | 11 (52) | 14 (41) |
| Objective response rate, n (%) | 7 (54) | 7 (33) | 14 (41) |
| 95% CI for objective response rate† | 25.1, 80.8 | 14.6, 57 | 24.6, 59.3 |
| Disease control rate, n (%)‡ | 10 (77) | 10 (48) | 20 (59) |